Grant and Funding Programs Offered by Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)
Overview of Available Grants and Funding
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a rare hereditary neurodegenerative disorder that primarily affects coordination, muscle control, and mobility. First identified in the Charlevoix-Saguenay region of Quebec, Canada, ARSACS is characterized by progressive spasticity, ataxia, and peripheral neuropathy, often beginning in childhood. The disease is caused by mutations in the SACS gene and is inherited in an autosomal recessive manner, meaning that both parents must carry the defective gene for their child to be affected. View Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)'s website for more information.
Content last updated: March 4, 2026
About Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)
What is the mission of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)?
The Foundation’s mission is to contribute to the discovery and development of an effective treatment for Autosomal Recessive Spastic Ataxia of Charlevoix‑Saguenay by financing high‑quality research, supporting clinical and preclinical studies, and building global collaborations around this rare neurological disease.
What type of organization is Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)?
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a Foundation.
When was Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) founded?
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) was founded in 2006.
What is Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)'s official website?
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)'s official website is https://www.arsacs.com.